Effects of Inoculum and β-Lactamase Activity in AmpC- and Extended-Spectrum β-Lactamase (ESBL)-Producing Escherichia coli and Klebsiella pneumoniae Clinical Isolates Tested by Using NCCLS ESBL Methodology

Journal of Clinical Microbiology

Volumn 42, Issue 1, 2004, Pages 269-275

  Queenan, Anne Marie ^a   Foleno, Barbara ^a   Gownley, Colleen ^a   Wira, Ellyn ^a   Bush, Karen ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAMASE; CEFALORIDINE; CEFEPIME; CEFOTAXIME; CEFPODOXIME; CEFTAZIDIME; CLAVULANIC ACID; EXTENDED SPECTRUM BETA LACTAMASE; NITROCEFIN; PENICILLIN G; TAZOBACTAM; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIAL STRAIN CTX M 10; BACTERIAL STRAIN K1; BACTERIAL STRAIN SHV 18; BACTERIAL STRAIN TEM 10; BACTERIAL STRAIN TEM 12; BACTERIAL STRAIN TEM 3; BACTERIAL STRAIN TEM 6; BACTERIUM ISOLATION; BINDING KINETICS; COLONY FORMING UNIT; DILUTION; ENZYME ACTIVITY; ENZYME ANALYSIS; ESCHERICHIA COLI; EVALUATION; HYDROLYSIS; INOCULATION; KLEBSIELLA PNEUMONIAE; METHODOLOGY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREDICTION; PRIORITY JOURNAL;

BACTERIAL PROTEINS; BETA-LACTAMASES; CEPHALOSPORINS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; HUMANS; HYDROLYSIS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; PENICILLIN G;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; KLEBSIELLA; KLEBSIELLA PNEUMONIAE; NEGIBACTERIA;

EID: 0347093260     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.42.1.269-275.2004     Document Type: Article

References (34)

1. Bedenic, B., N. Beader, and Z. Zagar. 2001. Effect of inoculum size on the antibacterial activity of cefpirome and cefepime against Klebsiella pneumoniae strains producing SHV extended-spectrum β-lactamases. Clin. Microbiol. Infect. 7:626-635.
2. Bradford, P. A. 2001. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 14:933-951.
3. Bradford, P. A., C. E. Cherubin, V. Idemyor, B. A. Rasmussen, and K. Bush. 1994. Multiply resistant Klebsiella pneumoniae strains from two Chicago hospitals: identification of the extended-spectrum TEM-12 and TEM-10 ceftazidime-hydrolyzing β-lactamases in a single isolate. Antimicrob. Agents Chemother. 38:761-766.
4. Bradford, P. A., N. V. Jacobus, N. Bhachech, and K. Bush. 1996. TEM-28 from an Escherichia coli clinical isolate is a member of the His-164 family of TEM-1 extended-spectrum β-lactamases. Antimicrob. Agents Chemother. 40:260-262.
5. Bradford, P. A., C. Urban, N. Mariano, S. J. Projan, J. J. Rahal, and K. Bush. 1997. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1. a plasmid-mediated AmpC β-lactamase, and the loss of an outer membrane protein. Antimicrob. Agents Chemother. 41:563-569.
6. Brenwald, N. P., G. Jevons, J. M. Andrews, J.-H. Xiong, P. M. Hawkey, and R. Wise. 2003. An outbreak of a CTX-M-type β-lactamase-producing Klebsiella pneumoniae: the importance of using cefpodoxime to detect extended-spectrum β-lactamases. J. Antimicrob. Chemother. 51:195-196.
7. Bush, K. 1989. Classification of β-lactamases: groups 1, 2a, 2b, and 2b′. Antimicrob. Agents Chemother. 33:264-270.
8. Bush, K. 2001. New β-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin. Infect. Dis. 32:1085-1089.
9. Bush, K., G. A. Jacoby, and A. A. Medeiros. 1995. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39:1211-1233.
10. Bush, K., and S. B. Singer. 1989. Effective cooling allows sonication to be used for liberation of β-lactamases from Gram-negative bacteria. J. Antimicrob. Chemother. 24:82-84.
11. Datta, N., and M. H. Richmond. 1966. The purification and properties of a penicillinase whose synthesis is mediated by an R-factor in Escherichia coli. Biochem. J. 98:204-209.
12. Fung-Tomc, J., T. J. Dougherty, F. J. DeOrio, V. Simich-Jacobson, and R. E. Kessler. 1989. Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to β-lactamase levels. Antimicrob. Agents Chemother. 33:498-502.
13. Jett, B. D., D. J. Ritchie, R. Reichley, T. C. Bailey, and D. F. Sahm. 1995. In vitro activities of various β-lactam antimicrobial agents against clinical isolates of Escherichia coli and Klebsiella spp. resistant to oxyimino cephalosporins. Antimicrob. Agents Chemother. 39:1187-1190.
14. Miro, E., M. del Cuerpo, F. Navarro, M. Sabate, B. Mirelis, and G. Prats. 1998. Emergence of clinical Escherichia coli isolates with decreased susceptibility to ceftazidime and synergic effect with co-amoxiclav due to SHV-1 hyperproduction. J. Antimicrob. Chemother. 42:535-538.
15. Naumovski, L., J. P. Quinn, D. Miyashiro, M. Patel, K. Bush, S. B. Singer, B. Graves, T. Palzkill, and A. M. Arvin. 1992. Outbreak of ceftazidime resistance due to a novel extended-spectrum β-lactamase in isolates from cancer patients, Antimicrob. Agents Chemother. 36:1991-1996.
16. NCCLS. 2003. Performance standards for antimicrobial susceptibility testing. NCCLS approved standard M100-S13 (M2), National Committee for Clinical Laboratory Standards, Wayne, Pa.
17. NCCLS. 2003. Performance standards for antimicrobial susceptibility testing. NCCLS approved standard M100-S13 (M7). National Committee for Clinical Laboratory Standards, Wayne, Pa.
18. Nikaido, H., W. Liu, and E. Y. Rosenberg. 1990. Outer membrane permeability and β-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents. Antimicrob. Agents Chemother. 34:337-342.
19. Oliver, A., J. C. Perez-Diaz, T. M. Coque, F. Baquero, and R. Canton. 2001. Nucleotide sequence and characterization of a novel cefotaxime-hydrolyzing β-lactamase (CTX-M-10) isolated in Spain. Antimicrob. Agents Chemother. 45:616-620.
20. Oliver, A., L. M. Weigel, J. K. Rasheed, J. E. J. McGowan, P. Raney, and F. C. Tenover. 2002. Mechanisms of decreased susceptibility to cefpodoxime in Escherichia coli. Antimicrob. Agents Chemother. 46:3829-3836.
21. Papanicolaou, G. A., A. A. Medeiros, and G. A. Jacoby. 1990. Novel plasmid-mediated β-lactamase (MIR-1) conferring resistance to oxyimino- and alpha-methoxy β-lactams in clinical isolates of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 34:2200-2209.
22. Paterson, D. L., W. C. Ko, A. Von Gottberg, J. M. Casellas, L. Mulazimoglu, K. P. Klugman, R. A. Bonomo, L. B. Rice, J. G. McCormack, and V. L. Yu. 2001. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum β-lactamases: implications for the clinical microbiology laboratory. J. Clin. Microbiol. 39:2206-2212.
23. Paul, G. C., G. Gerbaud, A. Bure, A. M. Philippon, B. Pangon, and P. Courvalin. 1989. TEM-4, a new plasmid-mediated beta-lactamase that hydrolyzes broad-spectrum cephalosporins in a clinical isolate of Escherichia coli. Antimicrob. Agents Chemother. 33:1958-1963.
24. Petrocheilou, V., R. B. Sykes, and M. H. Richmond. 1977. Novel R-plasmid-mediated β-lactamase from Klebsiella aerogenes. Antimicrob. Agents Chemother. 12:126-128.
25. Queenan, A. M., S. Jenkins, and K. Bush. 2001. Cloning and biochemical characterization of FOX-5, an AmpC-type plasmid-encoded β-lactamase from a New York City Klebsiella pneumoniae clinical isolate. Antimicrob. Agents Chemother. 45:3189-3194.
26. Rasheed, J. K., G. J. Anderson, H. Yigit, A. M. Queenan, A. Domenech-Sanchez, J. Swenson, J. W. Biddle, M. J. Ferraro, G. A. Jacoby, and F. C. Tenover. 2000. Characterization of the extended-spectrum β-lactamase reference strain, Klebsiella pneumoniae K6 (ATCC 700603), which produces the novel enzyme SHV-18. Antimicrob. Agents Chemother. 44:2382-2388.
27. Rasmussen, B. A., P. A. Bradford, J. P. Quinn, J. Wiener, R. A. Weinstein, and K. Bush. 1993. Genetically diverse ceftazidime-resistant isolates from a single center: biochemical and genetic characterization of TEM-10 β-lactamases encoded by different nucleotide sequences. Antimicrob. Agents Chemother. 37:1989-1992.
28. Sirot, D., J. Sirot, R. Labia, A. Rorand, P. Courvalin, A. Darfeuille-Michaud, R. Perroux, and R. Cluzel. 1987. Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: identification of CTX-1, a novel β-lactamase. J. Antimicrob. Chemother. 20:323-334.
29. Soriano, F., P. Garcia-Corbeira, C. Ponte, R. Fernandez-Roblas, and I. Gadea. 1996. Correlation of pharmacodynamic parameters of five β-lactam antibiotics with therapeutic efficacies in an animal model. Antimicrob. Agents Chemother. 40:2686-2690.
30. Szabo, D., A. Mathe, Z. Filetoth, P. Anderlik, L. Rokusz, and F. Rozgony. 2001. In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum β -lactamase-producing Klebsiella pneumoniae strain. Antimicrob. Agents Chemother. 45: 1287-1291.
31. Thomson, K. S., and E. S. Moland. 2001. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum β-lactamase-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 45:3548-3554.
32. Venkatachalam, K. V., W. Huang, M. LaRocco, and T. Palzkill. 1994. Characterization of TEM-1 β-lactamase mutants from positions 238 to 241 with increased catalytic efficiency for ceftazidime. J. Biol. Chem. 269:23444-23450.
33. Wong-Beringer, A., J. Hindler, M. Loeloff, A. M. Queenan, N. Lee, D. A. Pegues, J. P. Quinn, and K. Bush. 2002. Molecular correlation for the treatment outcomes in bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae with reduced susceptibility to ceftazidime. Clin. Infect. Dis. 34:135-146.
34. Yang, Y., N. Bhachech, P. A. Bradford, B. D. Jett, D. F. Sahn, and K. Bush. 1998. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli isolates producing TEM-10 and TEM-43 β-lactamases from St. Louis, Missouri. Antimicrob. Agents Chemother. 42:1671-1676.